ProNAi Therapeutics (DNAI) Misses Q2 EPS by 5c

ProNAi Therapeutics (NASDAQ: DNAI) reported Q2 EPS of ($0.43), $0.05 worse than the analyst estimate of ($0.38).

At June 30, 2016, ProNAi had $130.6 million in cash and cash equivalents compared to $150.2 million in cash and cash equivalents at December 31, 2015.

For earnings history and earnings-related data on ProNAi Therapeutics (DNAI) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c